KR101366868B1 - 약물 내성 종양의 치료 - Google Patents

약물 내성 종양의 치료 Download PDF

Info

Publication number
KR101366868B1
KR101366868B1 KR1020087016809A KR20087016809A KR101366868B1 KR 101366868 B1 KR101366868 B1 KR 101366868B1 KR 1020087016809 A KR1020087016809 A KR 1020087016809A KR 20087016809 A KR20087016809 A KR 20087016809A KR 101366868 B1 KR101366868 B1 KR 101366868B1
Authority
KR
South Korea
Prior art keywords
isomerase
tumor
drug
treatment
camptothecin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020087016809A
Other languages
English (en)
Korean (ko)
Other versions
KR20080078055A (ko
Inventor
클라우디오 피사노
로레다나 베시
Original Assignee
시그마타우 인두스트리에 파르마슈티케 리우니테 에스.피.에이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 시그마타우 인두스트리에 파르마슈티케 리우니테 에스.피.에이. filed Critical 시그마타우 인두스트리에 파르마슈티케 리우니테 에스.피.에이.
Publication of KR20080078055A publication Critical patent/KR20080078055A/ko
Application granted granted Critical
Publication of KR101366868B1 publication Critical patent/KR101366868B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Enzymes And Modification Thereof (AREA)
KR1020087016809A 2005-12-21 2006-12-13 약물 내성 종양의 치료 Expired - Fee Related KR101366868B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05027997.5 2005-12-21
EP05027997 2005-12-21
PCT/EP2006/069666 WO2007071603A1 (en) 2005-12-21 2006-12-13 Treatment of drug-resistant tumors

Publications (2)

Publication Number Publication Date
KR20080078055A KR20080078055A (ko) 2008-08-26
KR101366868B1 true KR101366868B1 (ko) 2014-02-21

Family

ID=35911064

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020087016809A Expired - Fee Related KR101366868B1 (ko) 2005-12-21 2006-12-13 약물 내성 종양의 치료

Country Status (19)

Country Link
US (1) US7888368B2 (enExample)
EP (1) EP1962850B1 (enExample)
JP (1) JP5657205B2 (enExample)
KR (1) KR101366868B1 (enExample)
CN (1) CN101340910B (enExample)
AT (1) ATE548038T1 (enExample)
AU (1) AU2006328607B2 (enExample)
BR (1) BRPI0620209A2 (enExample)
CA (1) CA2631868C (enExample)
CY (1) CY1112814T1 (enExample)
DK (1) DK1962850T3 (enExample)
EA (1) EA016487B1 (enExample)
ES (1) ES2382819T3 (enExample)
HR (1) HRP20120359T1 (enExample)
PL (1) PL1962850T3 (enExample)
PT (1) PT1962850E (enExample)
RS (1) RS52272B (enExample)
SI (1) SI1962850T1 (enExample)
WO (1) WO2007071603A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008098701A1 (en) * 2007-02-13 2008-08-21 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Broad-spectrum anti-cancer treatment based on iminocamptothecin derivatives
JP5765937B2 (ja) * 2007-08-01 2015-08-19 シグマ−タウ・インドゥストリエ・ファルマチェウチケ・リウニテ・ソシエタ・ペル・アチオニＳｉｇｍａ−Ｔａｕ Ｉｎｄｕｓｔｒｉｅ Ｆａｒｍａｃｅｕｔｉｃｈｅ Ｒｉｕｎｉｔｅ Ｓｏｃｉｅｔａ Ｐｅｒ Ａｚｉｏｎｉ 小児腫瘍の治療

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1282673B1 (it) * 1996-02-23 1998-03-31 Ist Naz Stud Cura Dei Tumori Derivati della camptotecina e loro uso come agenti antitumorali
PT1044977E (pt) * 1999-03-09 2002-09-30 Sigma Tau Ind Farmaceuti Derivados de camptotecina com actividade antitumoral

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Sabrina Dallavalle et al., J. Med. Chem. 2001, 44, 3264-3274 (2001.9.5. 공개) *
Sabrina Dallavalle et al., J. Med. Chem. 2001, 44, 3264-3274 (2001.9.5. 공개)*

Also Published As

Publication number Publication date
CN101340910A (zh) 2009-01-07
EP1962850A1 (en) 2008-09-03
HRP20120359T1 (hr) 2012-06-30
JP2009520754A (ja) 2009-05-28
CN101340910B (zh) 2012-12-12
WO2007071603A1 (en) 2007-06-28
DK1962850T3 (da) 2012-06-18
ES2382819T3 (es) 2012-06-13
EA016487B1 (ru) 2012-05-30
US7888368B2 (en) 2011-02-15
PL1962850T3 (pl) 2012-07-31
AU2006328607A1 (en) 2007-06-28
CA2631868C (en) 2014-02-11
HK1124776A1 (zh) 2009-07-24
CA2631868A1 (en) 2007-06-28
BRPI0620209A2 (pt) 2011-11-01
PT1962850E (pt) 2012-05-21
ATE548038T1 (de) 2012-03-15
AU2006328607B2 (en) 2012-04-19
JP5657205B2 (ja) 2015-01-21
EP1962850B1 (en) 2012-03-07
CY1112814T1 (el) 2016-02-10
EA200870073A1 (ru) 2009-12-30
RS52272B (sr) 2012-10-31
KR20080078055A (ko) 2008-08-26
SI1962850T1 (sl) 2012-06-29
US20080312265A1 (en) 2008-12-18

Similar Documents

Publication Publication Date Title
KR930009357B1 (ko) 수용성 캠프토테신 유도체 및 이의 제조방법
Chen et al. A new mammalian DNA topoisomerase I poison Hoechst 33342: cytotoxicity and drug resistance in human cell cultures
US6218399B1 (en) Derivatives of camptothecin and methods of treating cancer using these derivatives
Lavergne et al. Homocamptothecins: synthesis and antitumor activity of novel E-ring-modified camptothecin analogues
Pantazis et al. Complete inhibition of growth followed by death of human malignant melanoma cells in vitro and regression of human melanoma xenografts in immunodeficient mice induced by camptothecins
EP2976333B1 (en) Quinolines derivatives as novel anticancer agents
Kawato et al. Inhibitory activity of camptothecin derivatives against acetylcholinesterase in dogs and their binding activity to acetylcholine receptors in rats
Kurtzberg et al. Genz-644282, a novel non-camptothecin topoisomerase I inhibitor for cancer treatment
EP3844166B1 (en) Substituted macrocycles useful as kinase inhibitors
JPH11506453A (ja) 水溶性カンプトテシン類似体
KR101366868B1 (ko) 약물 내성 종양의 치료
EP0828743A1 (en) Water soluble camptothecin analogs
Rahier et al. Water-soluble camptothecin derivatives that are intrinsic topoisomerase I poisons
Wang et al. Antisense anti-MDM2 mixed-backbone oligonucleotides enhance therapeutic efficacy of topoisomerase I inhibitor irinotecan in nude mice bearing human cancer xenografts: in vivo activity and mechanisms
De Cesare et al. Preclinical efficacy of ST1976, a novel camptothecin analog of the 7-oxyiminomethyl series
US6407118B1 (en) Derivatives of camptothecin and methods of treating cancer using these derivatives
Feng et al. Synthesis of N-substituted 5-[2-(N-alkylamino) ethyl] dibenzo [c, h][1, 6] naphthyridines as novel topoisomerase I-targeting antitumor agents
Beretta et al. Biological properties of IDN5174, a new synthetic camptothecin with the open lactone ring
CN115814095A (zh) Rad51抑制剂和抗癌治疗剂的组合
Samor et al. The role of polyamine architecture on the pharmacological activity of open lactone camptothecin− polyamine conjugates
HK1124776B (en) Treatment of drug-resistant tumors
Cao et al. Structure-activity relationship of alkyl 9-nitrocamptothecin esters
Cao et al. Anticancer activity of new haloalkyl camptothecin esters against human cancer cell lines and human tumor xenografts grown in nude mice
SK397391A3 (sk) 9,10-Substituované kamptotecíny, farmaceutický prípravok s ich obsahom a medziprodukt
I-targeted Homocamptothecin, an E-Ring Modified Camptothecin with

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R17-X000 Change to representative recorded

St.27 status event code: A-5-5-R10-R17-oth-X000

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20170218

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20170218